Anagram Therapeutics's $250M: A Big Biotech Bet Amid AI's Spotlight
Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.
investment-strategies
-
-
Greycroft Leads Jesse & Ben’s $10M and Recursive Series A Rounds
Greycroft led Jesse & Ben’s $10M Series A clean-label food round and Recursive Superintelligence’s Series A, spanning consumer brands and AI.
-
Two Sigma Ventures Spins Out as Deviation Capital With $2B AUM
Two Sigma Ventures completed its spinout from quant firm Two Sigma to become independent Deviation Capital, carrying ~$2B in AUM and 79 portfolio companies.
-
Notation Capital Backs Photon Health $16M Series A
Notation Capital backed Photon Health’s $16M Series A, a follow-on to its earlier lead, staying true to its NYC pre-seed roots.
-
Forerunner Ventures Leads Casa Series A for Homeownership OS
Forerunner Ventures led the Series A for Casa, a homeownership operating system, continuing to deploy its $500M Fund VII into consumer-facing software.
-
AlleyCorp Leads Clarasight $11.5M Series A for Enterprise T&E AI
AlleyCorp led Clarasight’s $11.5M Series A to modernize enterprise travel and expense management with AI, part of a fast start to 2026 for the NYC firm.